×

Collegium to Present Xtampza ER(TM) Oral Human Abuse Potential Data at the College on Problems of Drug Dependence 77th Annual Meeting

CANTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the presentation of a scientific poster at the College on Problems of Drug Dependence 77th Annual Meeting, held at the Arizona Biltmore in Phoenix, AZ from June 13 to June 18.

The poster, titled "Oral Human Abuse Potential of Oxycodone DETERx®: An Abuse-deterrent, Extended-release Formulation in Recreational Opioid Users", summarizes data from a human abuse potential (HAP) study designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza ER™ (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release (IR) oxycodone in non-dependent, recreational drug abusers.

The oral HAP study demonstrated that chewed Xtampza ER had significantly lower peak "Drug Liking" (Emax) when compared with crushed IR oxycodone (p < 0.0001). Furthermore, there was no difference in the pharmacokinetics when Xtampza ER was chewed or taken intact as determined by bioequivalence measures (Cmax and AUC).

Poster #29

Title: Oral Human Abuse Potential of Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation in Recreational Opioid Users

Presenting Author: Ernest A. Kopecky, Ph.D., Vice President of Clinical Development and Head of Neuroscience, Collegium Pharmaceutical, Inc.

Date and Time: Tuesday, June 16, 2015, 11:30 am – 1:30 pm PT

Location: Arizona Biltmore, Phoenix, AZ

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. The new drug application, or NDA, filing for Xtampza ER, the Company's lead product candidate, was accepted by the FDA on February 10, 2015. The FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October 12, 2015 for completion of its review of the Xtampza ER NDA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that we will obtain approval for Xtampza or any of our other product candidates from the U.S. Food and Drug Administration ("FDA") or foreign regulatory authorities; even if Xtampza is approved, we may not be able to obtain the label claims that we are seeking from the FDA. Furthermore, we are subject to patent infringement litigation relating to Xtampza and may, in the future, be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our product candidates; the size and growth potential of the markets for our product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in the registration statement on Form S-1 (commission file number 333-203208), which was declared effective by the Securities and Exchange Commission ("SEC") on May 6, 2015. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CONTACT: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com

Source:Collegium Pharmaceutical